Company intelligence / Profile preview
Vittoria Biotherapeutics
Philadelphia, Pennsylvania, United Statesvittoriabio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
VIPER-101, a gene-edited autologous dual-population CD5-knockout CAR-T therapy for relapsed/refractory T-cell lymphoma, has entered Phase 1 dose escalation trials as of late 2024. Preclinical data show superior efficacy compared to classical CD5-targeted CAR-T therapies. The Senza5 platform enables enhanced potency and durability through modulation of CD5 signaling and a rapid five-day manufacturing process.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Autologous CAR-T cell therapies with gene editing technology
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Leukemia & Lymphoma Society (LLS)University of Pennsylvania (technology license)Tellus BioVenturesAgent CapitalValley Forge Investment CorporationBioAdvanceNYBC Ventures
Beyond the preview
Go deeper on Vittoria Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vittoria Biotherapeutics.